Legend Biotech Corp. (LEGN) PT Lowered to $91 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
January 22, 2025 11:11 AM ESTGoldman Sachs analyst Ziyi Chen reiterated a Buy rating and $84.28 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "JNJ/Legend reported preliminary sales of US$335mn (+17% q/q, +111% y/y, vs. GSe of US$299mn, 4Q company-provided consensus... More
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
January 21, 2025 6:39 AM ESTH.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $73.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst commented: "Concerns remain of a world where Arcellxs (ACLX; Buy; Bodnar) ddBCMA and CARVYKTI coexist commercially, with persistent investor questions about the market share splits. Anito-cel has shown zero non-ICANS delayed neurotoxicity (including parkinsonism) in >150 patients to... More
